James Norris reviews directors buying and selling shares in their own company over the last week in his weekly column
- CFO of Calnex Solutions sells-down exposure on strong results
- Braveheart CEO continues buying up own shares; increases Chamberlin holdings
- Augmentum NEDs buy on strong sentiment
- Director of AssetCo buys on massive opportunity
- NED buys Tritax shares
Calnex Solutions LON:CLX, a provider of telecoms testing equipment and solutions, has announced that chief financial officer Ashleigh Greenan sold 10,000 shares at 153p for GBP15,300, and then with the price up to 160p, she sold 3,000 more, for GBP4,800. The company’s FY21 results were strong, demand for telecoms testing equipment has remained strong and the order backlog has continued to grow. At close of trading yesterday, the stock was priced at 150.5p, a return of 24.90% YTD and 51.96% over 12 months.
Braveheart Investment Group LON:BRH chief executive, Trevor Brown continues to buy shares in his company. On 8th July, he bought 75,000 shares valued at 11.67p each, for a total of GBP8,750. So far this year, he has bought 562,500 shares in the company at prices ranging from 11.5p to 12.0p. Braveheart is an investment company that acquires businesses with potential for outperformance, with a portfolio that includes Paraytec Ltd (100% owned), Phasefocus Holdings (42.67%) and Kirkstall Ltd (80%). At close of trading yesterday, the stock was priced at 13.0p, a return of -62.86% YTD and -70.08% over 12 months.
On the same day, Brown also bought shares in Chamberlin LON:CMH, a specialist castings and engineering company, where he is director of strategy. He bought 1,250,000 shares at an average of 5.0p each in two tranches, for an aggregate GBP62,310. Alongside his role as chief executive of Braveheart, Brown is also chief executive of IQ-AI Ltd, and was previously a director of Feedback plc, Management Resource Solutions plc, Advanced Oncotherapy and Remote Monitored Systems. At close of trading yesterday, the stock was priced at 4.9p, a return of -32.15% YTD and -53.79% over 12 months.
Augmentum Fintech [LON:AUGM] non-executive director Neil England has bought two tranches of shares in the company. The first, acquired on 7th July, was of 20,000 shares at 119p, for GBP23,800; the second, on 8th July was another 20,000 shares at 117p for GBP23,500. Yesterday, on 11th July, fellow non-executive director William Russell bought 15,000 shares at 115p, for GBP17,250. Augmentum is a venture investment firm focusing on the fintech sector, backing fintechs such as Zopa and Tide. Economic uncertainty and the changing geopolitical situation in Europe have contributed to the company’s slowdown in fintech investment over the past year, but the firm’s belief in the sector is ‘as strong as ever’. At close of trading yesterday, the stock was priced at 115.5p, a return of -28.01% YTD and -21.51% over 12 months.
AssetCo LON:ASTO director Jonathan Dawson has bought 19,000 shares at 793p each for a total of GBP150,670. Assetco, taken over as a cash shell by former Standard Life Aberdeen boss Martin Gilbert, acquires asset managers and, with names such as River & Mercantile and SVM under its belt, it currently has GBP12.2bn in assets under management. The company’s portfolio companies are having to contend with several significant structural shifts in the asset management sector, but Gilbert says the current conditions offered: “a massive opportunity for active asset managers to outperform”. At close of trading yesterday, the stock was priced at 782.5p, a return of -51.02% YTD and -64.31% over 12 months.
Tritax Eurobox [LON:EBOX] non-executive director Robert Orr has bought 113,131 shares at 87.0p, paying GBP97,999.73. Tritax Eurobox, which invests in a portfolio of logistics assets across continental Europe, is on track for rapid growth, having last year secured GBP400m to develop its portfolio of assets. At close of trading yesterday, the stock was priced at 85.9p, a return of -26.61% YTD and -25.59% over 12 months.
This article is not investment advice. Investors should do their own research or consult a professional advisor.
